<DOC>
	<DOC>NCT01500486</DOC>
	<brief_summary>This study is conducted in Europe. The aim of this study is to evaluate ease of injection of growth hormone in patients using Norditropin NordiFlex® with NordiFlex PenMate™. Convenience and tolerability of NordiFlex PenMate™ - an automatic injection and a needle hiding device - is also evaluated.</brief_summary>
	<brief_title>Observational Study of Norditropin NordiFlex® With NordiFlex PenMate™</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism, Pituitary</mesh_term>
	<criteria>After the physician decision has been made to use Norditropin Nordiflex® growth hormone therapy in accordance with the locally approved labelling, any subject is eligible for the study, including newly diagnosed subjects who have never received growth hormone therapy before and subjects who were treated with the other growth hormone products (with exclusion of patients who received previously Norditropin Nordiflex®) and need to be switched to a new product. The selection of the subjects will be at the discretion of the individual physician Contraindications to Norditropin® growth hormone therapy Subjects who have received Norditropin NordiFlex® prior to this study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>